StockData
RenovoRx, Inc. logo

RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.12+0.08 (+7.69%)

Close on Nov 18, 2026Market cap $50.55MP/E –Yield –

RenovoRx gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

RenovoRx's gross profit for the twelve months ending Jun 30, 2026 was $1.67M. For fiscal 2025 it was $796.00K, up 1751.2% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$796.00K+1751.2%
FY2024Dec 31, 2024$43.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$766.00K+183.7%
Q1 FY2026Mar 31, 2026$479.00K+365.0%
Q4 FY2025Dec 31, 2025$210.00K–
Q3 FY2025Sep 30, 2025$213.00K–
Q2 FY2025Jun 30, 2025$270.00K–
Q1 FY2025Mar 31, 2025$103.00K–

More RenovoRx figures

See a number that looks wrong?